3′, 4′-Bis-difluoromethoxycinnamoylanthranilate (FT061): an orally-active antifibrotic agent that reduces albuminuria in a rat model of progressive diabetic …

…, DM Shackleford, J Morizzi, Y Zhang, AK Powell…

文献索引：Williams, Spencer J.; Zammit, Steven C.; Cox, Alison J.; Shackleford, David M.; Morizzi, Julia; Zhang, Yuan; Powell, Andrew K.; Gilbert, Richard E.; Krum, Henry; Kelly, Darren J. Bioorganic and Medicinal Chemistry Letters, 2013 , vol. 23, # 24 p. 6868 - 6873

全文：HTML全文

被引用次数: 9

摘要

Abstract Cinnamoylanthranilates including tranilast have been identified as promising antifibrotics that can reduce fibrosis occurring in the kidney during diabetes, thereby delaying and/or preventing kidney dysfunction. Structure–activity relationships aimed at improving potency and metabolic stability have led to the discovery of FT061. This compound, which bears a bis-difluoromethoxy catechol, attenuates TGF-β-stimulated ...